Elsevier -- Pregnant women with epilepsy have long been the focus of investigations regarding the safety of anticonvulsant agents for the developing fetus. Prenatal exposure to selected antiseizure medications in monotherapy and polytherapy has been linked to increased risks for specific congenital malformations. More recently, dose-related deficits in cognitive performance have been demonstrated with prenatal exposure to valproate.
